Cincinnati Business Courier: UC makes dean for College of Medicine official
Andrew Filak, MD, leads medical school as bicentennial approaches
Cincinnati Business Courier reports the University of Cincinnati has named Dr. Andrew Filak, Jr., dean of the College of Medicine and senior vice president for health affairs. Filak, who has been serving in the role on an interim basis since August 2018, will officially assume the position January 1, 2020, pending approval by the UC Board of Trustees. Filak will oversee a medical college consisting off 25 departments with about 2,500 employees and almost 1,700 students. A 2016 UC Economics Center study concluded the College of Medicine has an economic impact of about $ 1billion in the region.
Filak has more than four decades of experience at the UC College of Medicine, UC Medical Center, and the UC Academic Heath Center. Prior to his position as interim dean, Dr. Filak served as senior associate dean for academic affairs, founding chair of the Department of Medical Education and professor of medical education and family and community medicine at the UC College of Medicine. He also served as vice president for education for UC Health.
Related Stories
Fall grads celebrate their success at commencement
December 12, 2025
The University of Cincinnati recognized more than 2,600 graduates at its fall commencement.
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.